Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

J Neural Transm. 1978;43(3-4):271-7. doi: 10.1007/BF01246964.

Abstract

Deprenyl is an inhibitor of monoamine oxidase type B, the enzyme responsible for 2-phenylethylamine oxidation, and is used in conjunction with L-Dopa therapy in Parkinson's disease. Post-mortem studies in human brain tissue have shown that after (-)deprenyl administration to parkinsonian patients amphetamine is present in concentrations up to 56 ng/g. It also could be shown that phenylethylamine concentrations are substantially increased in such patients. Phenylethylamine and amphetamine have been investigated using a gas chromatographic technique.

MeSH terms

  • Amphetamines / metabolism*
  • Brain / metabolism*
  • Humans
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Phenethylamines / metabolism*
  • Phenethylamines / therapeutic use*
  • Selegiline / therapeutic use*

Substances

  • Amphetamines
  • Phenethylamines
  • Selegiline